Company Profile
InMed Stock Price, News & Catalysts
- Ticker:
- INM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada and listed in the U
Stock performance
1.35 USD (-0.74%)
Close
Last updated: October 1, 2026
5.04M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, INM closed down 0.74% at $1.35. No new same-company headline was identified in the current news window.
Company overview
Small-Molecule Drug Portfolio Company
InMed Pharmaceuticals has developed cannabinoid-related and other small-molecule candidates for neurological, ophthalmic, and dermatologic diseases. The company is seeking strategic transactions for its legacy development programs.
INM-901 for Alzheimer's Disease
INM-901 is a small-molecule candidate being explored for Alzheimer's disease. Preclinical work has evaluated potential effects on neuroinflammation, neuronal function, and disease-related pathology.
INM-089 for Dry AMD
INM-089 is being developed for dry age-related macular degeneration. The program is intended to address retinal degeneration through a differentiated small-molecule mechanism.
INM-755 Dermatology Program
INM-755 is a topical candidate that has been studied in dermatologic conditions, including symptoms associated with epidermolysis bullosa. It remains part of the portfolio available for licensing or other strategic development.
Transition from BayMedica
InMed discontinued operations at BayMedica, its rare-cannabinoid manufacturing subsidiary. The remaining strategy emphasizes monetization, licensing, or transfer of the pharmaceutical assets rather than maintaining a vertically integrated commercial cannabinoid business.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of InMed (INM)?
InMed (INM) most recently closed at 1.35 USD, a -0.74% move versus the previous session.
What is the market cap of InMed (INM)?
InMed currently has a market capitalization of 5.04M USD on BioPharmSignal.
What does InMed do?
Small-Molecule Drug Portfolio Company InMed Pharmaceuticals has developed cannabinoid-related and other small-molecule candidates for neurological, ophthalmic, and dermatologic diseases. The company is seeking strategic transactions for its legacy development programs. INM-901 for Alzheimer's Disease INM-901 is a small-molecule candidate being explored for...
On which exchange is INM stock listed?
InMed (INM) is associated with NASDAQ, Canada and listed in the U, Biopharma.
What is INM-901?
INM-901 for Alzheimer's Disease INM-901 is a small-molecule candidate being explored for Alzheimer's disease.
Which conditions is InMed targeting with INM-901?
InMed is associated with inflammatory disease, dermatology based on its company overview and current catalyst commentary.
What is INM-089?
INM-089 for Dry AMD INM-089 is being developed for dry age-related macular degeneration.
What is INM-755?
INM-755 Dermatology Program INM-755 is a topical candidate that has been studied in dermatologic conditions, including symptoms associated with epidermolysis bullosa.